The fact that relative ATM deficiency is seen in a proportion of stage I patients suggests that reduced ATM expression is an early event in NSCLC carcinogenesis and supports the hypothesis [29] that tumour progression is associated with a disruption in the ATM-CHK2-p53 pathway in many human cancers, including lung cancer. This evidence concerns the gene CHEK2 and lung carcinoma.